PYPD (PolyPid) Accounts Payable & Accrued Expense : $4.98 Mil (As of Mar. 2025)

View and export this data going back to 2020. Start your Free Trial

What is PolyPid Accounts Payable & Accrued Expense?

PolyPid's quarterly accounts payable & accrued expense increased from Sep. 2024 ($4.41 Mil) to Dec. 2024 ($4.95 Mil) and increased from Dec. 2024 ($4.95 Mil) to Mar. 2025 ($4.98 Mil).

PolyPid's annual accounts payable & accrued expense declined from Dec. 2022 ($3.55 Mil) to Dec. 2023 ($2.73 Mil) but then increased from Dec. 2023 ($2.73 Mil) to Dec. 2024 ($4.95 Mil).

PolyPid Accounts Payable & Accrued Expense Historical Data

The historical data trend for PolyPid's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PolyPid Accounts Payable & Accrued Expense Chart

PolyPid Annual Data

Trend

Dec13

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

2.64

7.81

3.55

2.73

4.95

PolyPid Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial															3.90	3.98	4.41	4.95	4.98

PolyPid Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

PolyPid Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PolyPid Ltd (NAS:PYPD) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

18 Hasivim Street, P.O Box 7126, Petach Tikva, ISR, 495376

Website

https://www.polypid.com

PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. Its product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.